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LEWIS, M. E., H. KHACHATUR~AN, H. AKIL AND S. J. WATSON. A~ut#~j~ul relati~~~ship brfrtwn i~piui~p~pti~e.s 
und receptors in rhrsus monkey brain. BRAIN RES BULL 13(6) 801-812, IYg4.--To determine whether opioid peptide- 
receptor pharmacological associations found in vitro (e.g., enkephalind, dynorphin-K) predict anatomical relationships in 
sitrc. immun~yt~hemic~ and receptor auto~d~ographic studies were carried out on adjacent sections from the same 
brains of fo~aldehyde-based rhesus monkeys. Apparent p and K opioid receptors [labeled, respectively, by L3H] naloxone 
and (3H]bremazocine under different incubation conditions), but not S opioid receptors (labeled by (3H]D-Ala*, D 
Leu~-enkeph~in), survived the fixation procedure, and were found to be colocalized throu~out the brain. We have 
observed complex associations between these binding sites and one, two, or all three opioid peptide systems (i.e., 
proopiomelan~o~in, proenkeph~in, and pr~yno~hin) in different brain regions. These muItiple opioid peptide-receptor 
subtype associations are apparent, for example, in neural systems involved in the processing of pain stimuli, and may be 
important for mediating different types of analgesia. Since differential processing of proenkephalin and prodynorphin can 
give rise to opioids of varying receptor selectivities, the colocalization of opioid receptor subtypes may signify that such 
processing is a key regulatory event in determining which receptor subtype is activated and, thus. the physiological 
consequences of opioid neurotransmission. 
Opioid receptor autoradiosraphy [“Hlnaloxone F7HJbremazocine Proopiomelanocortin Enkephalin 
Dynorphin Rhesus monkey brain 
THE existence of three precursors for opioid peptides has 
been clearly established by molecufar biological studies [8, 
16, 24, 45, 51-53, 62, 631. These precursors are: (I) 
proopiomeianoco~in (F’OMC), which gives rise to 
p-endorphin and its NH,-terminally acetylated and/or 
COOH-terminally cleaved forms; (2) proenkephalin, which 
contains four copies of Met-enkephalin and single copies of 
Leu-enkephalin, Met-enkephahn-Arg6-Phe’, and Met- 
~nkephaIin-Arg~-Gly7-LeuH~ and gives rise to extended 
enkephahn peptides such as BAM-22P; and (3) prodynor- 
phin, which gives rise to ff-/~-Leo-endo~hin, dyno~hin A, 
and dynorphin B, ah of which contain the Leu-enkephahn 
sequence at the NH, terminus. The peptides derived from 
these three precursors are contained within three distinct 
sets of neural systems, as determined by numerous im- 
munocytochemical studies (see 11, 28, 37, 751 for reviews). 
Although the precursors are neuronally segregated, the 
enkephalin and dynorphin systems, in particular, exhibit 
substantial anatomical contiguities in many brain regions [ 17, 
25, 30, 48, 771. Given the anatomical complexity and 
biochemical relatedness of the muhiple opioid systems, it 
seems worth considering how the “messages” of these sys- 
tems are differentiated at the receptor level. Despite a wealth 
of pharmacological and biochemical evidence for the exist- 
ence of multiple opioid receptors (see [64] for review), the 
relationship of these receptors to multiple opioid systems is 
poorly understood. Nevertheless, pharmacological studies 
of the endogenous ligands have provided some rationale for 
making anatomical predictions of ligand-receptor associa- 
tions. While the pentapeptide enkeph~ins appear to bind 
preferentially to the 6 opioid receptor subtype [44], 
prodynorphin-related peptides are usually reported to ex- 
hibit selectivity for the K receptor subtype 17, 9, 57, St]. In 
contrast, p-endorphin binds equally well to the F and 6 
opioid receptor subtypes f44], but not to the K subtype 
[34,573. 
To begin to explore whether in vitro li8~d-receptor 
associations predicted anatomical relationships in situ, we 
found that it was possible to carry out opioid im- 
mun~yt~hemical and’receptor autoradjo~phic studies on 
adjacent sections from formaldehyde-perfused rat brain [38]. 
This initial study revealed an association, in many brain 
areas, between Leu-enkephaiin, a putative 8 ligand, and 
[:SH]naloxone binding sites, which appear to correspond to ~1 
opioid receptors under the conditions used. Further studies 
pointed to a complex relationship between [JHjnaloxone 
binding sites and all three opioid systems in rat brain (401, a 
finding also obtained in preliminary studies of rhesus mon- 
key brain (391, In the present report, we extend the study of 
rhesus monkey brain to describe the relationship between 
the multiple opioid peptide systems and apparent cr_ and K 
opioid receptors. 
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METHOD 
Adult rhesus monkeys (Macaca mulatta) were 
anesthetized with sodium pentobarbital (30 mg/kg, IV), re- 
spirated through an endotrachial tube, and perfused through 
the aorta with 2 liters of saline followed by 16 liters of 0.1 M 
phosphate-buffer 4% formaldehyde. Some animals were 
treated, under anesthesia, with coichicine (l-3 mg intracere- 
broventricuiarly) 48 hours prior to perfusion. Following per- 
fusion, the head was severed from the trunk, placed in a 
stereotaxic apparatus, and the top of the calvarium was re- 
moved. Within the skull, the brain was cut into 1 cm thick 
slices in the frontal or parasagital planes using a Kopf 
stereotaxic device with blades attached. The brain slices 
were removed from the skull, postfixed in buffered 4% for- 
maldehyde for 2-4 hours at 4”C, and then transferred into 
15% sucrose in 0.02 M phosphate-buffered saline (PBS) for 
overnight incubation at 4°C. The tissues were then frozen by 
immersion into isopentane at -50°C followed by encasement 
in pulverized dry ice, and stored in a freezer at -80°C. The 
frozen tissue blocks were sectioned at 20 pm in a Bright 
cryostat, and the sections were thaw-mounted onto subbed 
slides and stored in a freezer at -80°C. 
Immunocytochemistty 
Sections to be processed for immunocytochemistry were 
air-dried at room temperature and incubated at 37°C with 
normal goat serum (NGS, from GIBCO) at a dilution of l/30 
for 10 minutes, followed by primary rabbit antisera (diluted 
with PBS containing 0.3% Triton X-100) against ACTH (to 
label PGMC neurons), Leu-enkephalin, or dynorphin B(l- 
13) for one hour at 37°C and overnight at 4°C. Control sec- 
tions were incubated with primary antiserum preabsorbed 
with l-20 PM concentrations of peptide against which the 
antiserum was raised, as well as with other peptides with 
amino acid sequences in common with the original peptide. 
For these cross-blocking studies, the primary antisera were 
preabsorbed with Leu-enkephaiin, BAM-22P, dynorphin 
B(l-13), dynorphin A(l-17), /3-endorphin and ACTH (see 
[26,27,29-331 for antisera characteristics). The next day, the 
sections were washed in PBS (3 x 10 minutes) and incubated 
with NGS for 10 minutes at 37°C followed by goat antirabbit 
serum (Amei) at l/100 dilution for 30 minutes at 37°C and 
overnight at 4°C. On the third day, the sections were washed 
in PBS and incubated with NGS for 10 minutes at 37”C, 
followed by anti-horseradish peroxidase (anti-HRP) serum at 
l/200 dilution for 40 minutes at 37°C. The sections were again 
washed with PBS and incubated with PBS containing 4 &ml 
HRP enzyme (Sigma, Type VI) for 40 minutes at 37°C. The 
peroxidase reaction was carried out by incubat@g the sec- 
tions in PBS containing 0.03% H,O, and 0.125 mg/ml 
diaminobenzidine (Sigma) for 15 minutes at room tempera- 
ture with constant stirring. The reacted sections were 
washed in distilled water (3 x 10 minutes), briefly osmicated 
(2% OsOJ, washed, dehydrated through ascending concen- 
trations of ethanol and exyienes, and coverslipped in Per- 
mount. 
Receptor Autoradiography 
Sections adjacent or near to those processed for im- 
munocytochemistry were processed for opioid receptor au- 
toradiography [21,22,38-40,421. In rhesus monkey cerebral 
cortex, [3H]naloxone and E3H]D-Ala*, D-Leu5-enkephaiin. 
under carefully selected assay conditions, bind to different 
populations of sites which appear to correspond, respec- 
tively, to p and 6 opioid receptor subtypes [4, 21, 221. In 
addition, [3H]bremazocine, in the presence of uniabelled p 
and S ligands, appears to bind selectively to K opioid recep- 
tors [9]. To label apparent p sites, slide-mounted sections 
were incubated in 0.05 M Tris HCl (pH 7.55) containing 1 n&l 
[3H]naloxone (New England Nuclear, 37.7 Ci/mmOl) and 100 
mM NaCi at 4°C for 60 minutes. To label apparent 6 sites, 
adjacent or nearby slide-mounted sections were incubated in 
0.05 M Tris HCi (pH 7.4) containing 1 nM raH]D- 
Aia2,D-Leu5-enkephaiin (New England Nuclear, 39.5 
Ci/mmoi), 30 mM NaCi, 3 mM Mn(OAc),, 2 JLM guanosine 
triphosphate, 0.2% bovine serum albumin, and 80 pg baci- 
tracin/ml at 25°C for 30 minutes. To label apparent K sites. 
adjacent or nearby sections were incubated in 0.05 M Tris 
HCi (pH 7.4) containing 2 nM [3Hlbremazocine (New 
England Nuclear, 32.3 Ci/mmoi), 100 nM D-Ala’-MePhe4- 
Gly-olJ-enkephalin (DAGO), and 100 nM D-Thr*-Leu5- 
enkephaiin-Thp (DTLET) at 25°C for 60 minutes. 
Incubations were terminated by transferring the slides 
through dishes containing 200 ml (at 4”) of 0.1 M phosphate- 
buffered saline (pH 7.4) for the [3H]naloxdne-inctibated 
slides (6x 20 second washes) or 0.05 M Tris HCi buffer (p&I 
7.55) for the [3H]D-Ala2,D-Leu5-enkephaiin-incubated slides 
(6x 20 second washes) and [3H]bremazocine-incubated 
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FIG. 1. Competition of UM- 1071 (MR 2034) and morphine for specific r3~]brem~cine binding sites 
(in the presence of 100 nM DAGO and DTLET) in brain sections from formaldehyde-perfused rhesus 
monkey (determinations in quadruplicate). Note the three order-of-magnitude difference in potency, 
indicating the K selectivity of the binding. 
slides (4~ 4 minute washes). The slide-mounted sections 
were then dried under a stream of cold air. 
Nonspecific binding was determined by adding I-10 w.M 
levorphanol (for g and 6 binding) or UM-1071 (for K binding) 
to the incubation media for some sections, and then measur- 
ing the bound radioactivity to elution into scintillation fluid 
(Safety-Solve; Research Products Int. Corp.) followed by 
liquid scintillation counting. Other sections prepared for 
nonspecific binding were saved for autoradiography. 
The slide-mounted sections were processed for au- 
toradiography using one of two methods. Some slides were 
arranged in X-ray cassettes (Spectroline) and exposed to 
tritium-sensitive film (E”H]Ultrofilm, LKB) for 8-16 weeks. 
The film was developed in D-19 (Kodak) for 4 minutes at 
19”C, washed in 2% acetic acid for 30 seconds, fixed in 
Rapidfix (Kodak) for 5 minutes, rinsed in water for 20 min- 
utes, dried, and then photographed using an enlarger. Other 
slides were exposed to paraformaldehyde vapors in vucuo at 
80°C for 2 hours, demyelinated through ascending concen- 
trations of ethanol, xylenes, and descending concentrations 
of ethanol, dried, and coated, under safelight i~umination, 
with liquid emulsion (Kodak NTB2, diluted 1: 1 with 0.1% 
Dreft detergent) [22]. The emulsion-coated sections were 
exposed in light-proof boxes for 8-16 weeks at 4°C and then 
developed in D-19 for 2 minutes at 16”C, rinsed in water for 
15 seconds, fixed in Rapidfix for 3 minutes, rinsed in water 
for 45 minutes, counterstained lightly with cresyl violet, and 
coverslipped in Permount. These sections were compared, 
using darkfield optics, to adjacent or nearby sections which 
had been processed for immunocytochemistry. 
RESULTS 
Scintillation counting studies demonstrated that 
~jH]naloxone binding to rhesus monkey brain sections was 
approximately 90% specific, which is comparable to results 
obtained in previous studies of both formaldehyde-fixed 
[38,40] and unfixed [42] rat brain sections. In contrast, vir- 
tually no specific binding of [3H]D-A1aZ,D-LeuS-enkephalin 
co&d be detected in the fo~~dehyde-axed rhesus monkey 
brain sections. The efficacy of the labelling method was con- 
firmed by demonstrating 85-90% specific binding of the 
tritiated peptide in unfixed rhesus monkey brain sections 
(data not shown). Binding of [3H]bremazocine to both fixed 
and unfixed rhesus monkey brain sections was 90-9551 spe- 
cific. To examine the K selectivity of this binding, competi- 
tion studies were carried out with UM-1071 (MR 2034), a 
potent K agonist, and morphine, the prototypical t.& agonist 
(Fig. 1). Under the conditions used, UM-1071 was three or- 
ders of magnitude more potent than morphine (I&=2.4 nM 
and 2.2 PM, respectively) in competition with 
[“Hlbremazocine binding to fixed rhesus monkey brain sec- 
tions 
The LKB Ultrofilm and Kodak wet emulsion autoradio- 
graphic methods gave the same results for f3H]naloxone lo- 
calization, as reported before for rat brain [22,42]. However, 
bound [“Hlbremazocine was not successfully vapor-fixed 
(see [35]), and was therefore localized using only Ultrofilm. 
The anatomical loci of [3H]naloxone and [3H]bremazocine 
binding sites, using the incubation conditions described, 
were indistinguishable at every level of the central nervous 
system which was examined (e.g., Fig. 2). Thus, in the fol- 
lowing anatomical descriptions, these sites are referred to as 
opioid binding sites. 
The anatomical distribution of opioid binding sites is par- 
ticularly pronounced in brain regions which also contain 
subst~ti~ amounts of opioid immunore~tive structures 
[ 17, 25, 261. As an exception, however, the cerebral cortex 
and hippocampusldentate gyrus contain a readily visualized 
population of opioid binding sites (Fig. 6), but very little or 
no apparent opioid immunoreactive perikarya or fibers. In 
the striatal complex, distinct patches of [3H]opioid binding 
sites are seen scattered throughout the caudate (Fig. 2). Both 
enkephalin and dyno~hin immunorea~tivity also exist in 
neuronal perikarya as well as fibers in caudate. Furthermore, 
POMC-immunoreactive fibers are seen in the rostral-ventral 
aspect of the head of caudate and putamen. The exact 
anatomical relationship of these opioid systems to opioid 
X04 
receptors is not clear at preseennt, and as is the case in the 
rat brain 1401, no apparent correspondence is noted between 
receptor localization and peptide distribution. Enkephalin 
and dynorphin perikarya in caudate may project to the 
globus palhdus and the substantia nigra in monkey as they do 
in rat [71], but only modest levels of [3H]opioid binding sites 
are present in either of the latter two regions. Elsewhere in 
the telencephalon, the bed nucleus of stria terminalis con- 
tains a dense concentration of POMC fibers, enkephalin 
perikarya and terminals, and [“Hlopioid binding sites (Fig. 
3). Furthermore, in amygdala, the central and medial nuclei 
receive POMC projections, and contain enkephahn and 
dynorphin perikarya and fibers. Dense [DH]opioid binding is 
also seen in all regions of the amygdala. . 
In the preoptic area, the location of [“Hlopioid binding 
sites (Figs. 3 and 4) corresponds to the distribution of a dis- 
tinct bundle of immunoreactive POMC fibers coursing 
through this region. Numerous enkephalin and dynorphin 
neuronal perikarya and terminals also are seen scattered in 
the medial preoptic area. 
Within the diencephalon, a particularly good correspond- 
ence can be seen between opioid peptides and binding sites 
(Figs. 4 and 5). Unlike in the rat brain, the rhesus monkey 
hypothalamus is very rich in [DH]naloxone and 
[SH]bremazocine binding sites. For example, exceptionally 
heavy labelling is seen in the external layer of the median 
eminence. Here also, a particularly rich network of 
enkephahn and POMC terminals is seen surrounding the por- 
tal capillaries (Fig. 5). Opioid binding is also heavy in the 
magnocellular paraventricular (Fig. 4) and supraoptic (Fig. 2) 
nuclei, as well as periventricular and infundibaular nuclei 
(Fig. 4). The magnocellular nuclei contain high quantities of 
dynorphin (Fig. 2) synthesized by the same neurons that also 
produce vasopressin [74]. These cells may also contain 
Leu-enkephalin; however, the biosynthetic source of this 
peptide in the magnocellular neurons is not clear at pres- 
ent. The paraventricular, and to a lesser extent, the sup- 
raoptic nucleus, are both innervated by POMC fibers. The 
infundibular nucleus is very rich in both POMC perikarya 
and fibers (Fig. 4). This region also contains scattered 
enkephalin and dynorphin neurons some of which may con- 
tribute fibers to the median eminence. In contrast, the lateral 
and posterior hypothalamic areas contain both lower levels 
of opioid peptides and [“Hlopioid binding sites. In the 
thalamus, many nuclei are rich in [3H]opioid binding sites, 
and most of these nuclei also contain enkephalin im- 
munoreactivity. The correspondence is particularly striking 
in the midline periventricular nucleus, which exhibits a 
dense accumulation of both binding sites as well as POMC 
and enkephalin fibers (Fig. 5). 
In the region of midbrain, the interpeduncular nuclear 
complex contains a very dense population of [JH]opioid 
binding sites (Fig. 3). This nucleus also contains scattered 
enkephalin immunoreactive perikarya and fibers, yet is vir- 
tually devoid of any POMC immunoreactivity. Dorsally in 
midbrain, there is a clear correspondence in the relative 
densities of opioid binding sites and opioid immunoreactivity 
in the substantia grisea centralis (or periaqueductal gray). 
Here also, a distinct projection of POMC fibers is seen sur- 
rounding the cerebral aqueduct (Fig. 3). 
In the brainstem, the parabrachial nucleus is richly inner- 
vated by POMC and enkephalin fibers and terminals and 
contains a high density of opioid binding sites. Other pontine 
nuclei and regions are apparently devoid of opioid peptides 
and binding sites. In the medulla, a good correspondence 
I .I<WlS 1.7 :I I 
between all three opioid peptides and opioid binding sites is 
seen only in the nucleus tractuas solitarius and the spinal 
trigeminal nucleus. The latter nucleus, which is in effect the 
rostral extension of the spinal cord dorsal gray. is particu- 
larly rich in enkephalin immunoreactivity distributed in both 
perikarya and terminals, as well as [RH]opioid binding sites. 
DISCUSSION 
The present study has described anatomical relationships 
between multiple opioid immunoreactive systems and 
[“Hlnaloxone and [“Hlbremazocine binding sites in adjacent 
or nearby sections from formaldehyde-perfused rhesus mon- 
key brain. The preservation of [RH]naloxone binding sites 
following formaldehyde perfusion was also found for rat 
brain [38,40], and we report here that [“Hlbremazocine bind- 
ing sites are also maintained after fixation. These 
lSH]bremazocine binding sites, labelled in the presence of 
100 nM concentrations of DAGO, a selective p agonist [34], 
and DTLET, a selective 6 agonist [82] appear to correspond 
to K opioid receptors. Bremazocine is a very potent K ligand 
[65] which should be K-SdeCtiVe in the presence of excess 
concentrations of p and 6 ligands [9], as confirmed here in 
the competition experiment with UM-1071 (MR 2034) and 
morphine. The anatomical loci of [“Hlbremazocine binding 
sites corresponded exactly with the distribution of 
[“Hlnaloxone binding sites. Although the [RH]naloxone incu- 
bations were carried out in the absence of fi and K ligands. 
there is substantial evidence that low concentrations of 
[“Hlnaloxone, under the incubation conditions used, selec- 
tively label p opioid binding sites ([14, 21, 22, 56) but see 
[43]). Even if [3H]naloxone labelled K as well as p opioid 
receptors in rhesus monkey brain, the identical distribution 
of [:jH]naloxone and [“Hlbremazocine binding sites would 
still indicate the colocahzation of p and K receptors. Other- 
wise, the “p component” of [JH]naloxone binding sites 
would not correspond to the distribution of [nH]bremazocine 
binding sites. and some anatomical discrepancy would be 
apparent. Colocalization of /* and K opioid binding sites has 
also been reported in rat brain [56], but not in guinea pig [ 141 
or human [46] brain. The extent to which these findings re- 
flect authentic species differences [ lO,SS] or simply variation 
in the ways subtypes are labeled remains to be determined. 
However, in primates, a clear species difference does appear 
to be present: 13H]bremazocine, in the presence of p and 6 
ligands, binds heavily to interpeduncular nucleus in rhesus 
monkey brain (see Results), but not at all to this structure in 
human brain 1461. 
The apparent colocalization of g and K opioid receptors 
throughout rhesus monkey brain is in contrast to the differ- 
ential distribution of apparent JL and 6 opioid receptors in 
monkey cerebral cortex [41]. A similar pattern also holds for 
rat brain [ 15, 42, 591. We were unable to examine the distri- 
bution of 6 opioid receptors in the present study since virtu- 
ally all [“HID-Ala*, D-Leu”-enkephalin binding was 
abolished by formaldehyde perfusion. This fixation-induced 
loss of S binding was also observed for rat brain [40]. and 
may be indicative of a chemical difference in the opioid re- 
ceptor subtypes [23] or possibly a shift in receptor con- 
formation [4,5], possibilities which we cannot presently dis- 
criminate. 
The distribution of [“Hlnaloxone and [.‘H]bremazocine 
binding sites in formaldehyde-perfused rhesus monkey brain 
corresponds very closely to the localization previously re- 
ported in studies of unfixed brain with [:‘H]naloxone 1791 and 
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the supraoptic nucleus, end its correspondence with dynorphin B(l-13) immunoreactive neurons in this nucleus (A: inset). 
FIG. 3. A shows [3H]bremazocine binding sites in a parasagittal section. In adjacent sections B and C (see arrows in A). 
immunoreactive ACTH fibers are shown in the substantia grisea centralis (B) and the bed nucleus of stria terminalis (C). 
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FIG. 4. In A, [Wjbreammcinc biadiaesitesareseenina~~sectioncloseto~.B~C(az*,srrows~A)ere 
adjacent sections which show the distribution of ACTH immunorcactive fibers in the infmdibular nucleus (3) and the bed 
nucleus of anterior commissllre (C). 
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FIG. 5. ($HJ bremazocine bindti sites are seen in a mid-sauittal ulane (A\. In adiacent sections B and C (see arrows in A). 
ACTH immunor~ctive fibers &e seen in the ~~vent~c~~ar nucleus of thalamus (B), and diffuse JJ&enkephaiin im: 
munoreactivity is shown in the median eminence (Cf. 
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layer VI (arrow points to area TE, visual as~otl cortex), -, preaubhIum and subiculum, as well as 
stratum granulosum (e) and stratum moleculare (m) of the dentate gyrus. 
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[:‘H]dipremorphine [73]. The preservation of the anatomical 
distribution of [3H]naIoxone and 13H]bremazocine binding sites 
following formaldehyde perfusion has allowed us to perform 
receptor autoradiographic and opioid peptide immunocyto- 
chemical studies on adjacent sections from the same bmin. 
Although general anatomical relationships between endoge- 
nous ligands and receptors can be discerned by comparing 
tissue sections from brains processed differentially for im- 
munocytochemistry and autoradiography [69.70]. such com- 
parisons are difficult due to problems in section alignment, 
the complexity of receptor distribution, and the anatomical 
relatedness of the multiple opioid systems in many regions. 
Using adjacent section analysis. we have detected asso- 
ciations between apparent multiple opioid receptqrs and one. 
two, or all three opioid systems in many regions of rhesus 
monkey brain [39]. The neural systems involved in the pro- 
cessing of painful stimuli [ 1,3,36] provide a good example of 
these multiple associations. The spinal trigeminal nucleus, 
the rostra1 continuation of the spinal cord dorsal gray, is 
particularly rich in both enkephalin and dynorphin perikarya 
and terminals and apparent p and K opioid receptors. These 
peptide systems and receptors appear thoroughly interdigi- 
tated, at least at the light microscopic level. The 
periaqueductal gray, or substantia grisea centralis. contains 
substantial enkephalin and POMC (and some dynorphin) 
immunoreactivity which occurs in complex relation to the 
multiple opioid receptors. Stimulation of this region 
produces profound analgesia in monkeys 147,541 and humans 
[60.61], and the role of the multiple opioid systems and re- 
ceptors in mediating antinociception requires further study. 
Thalamic nuclei involved in pain processing (e.g., midline 
periventricular nucleus) also show a correspondence be- 
tween FQMC and enkephalin immunoreactivity and appar- 
ent p and K opioid receptors. While much attention has been 
focused on the role of p receptors in mediating opioid 
analgesia, K agonists also have significant antinociceptive 
actions, though apparently on different types of pain 16, 19, 
55. 67, 681. It is also worth noting that /* and K ligands 
produce centrally discriminable effects in rhesus monkeys 
[20,80]. Given the apparent colocahzation of p and K opioid 
receptors in the species used in the antinociception tests 
(rats) and drug discrimination paradigms (rhesus monkeys), 
the behavioral differentiation of p and K effects has interest- 
ing implications. These opioid receptor subtypes, although 
colocalized at the light microscopic level, may have different 
synaptic loci (e.g., pre- vs. post- vs. non-synaptic) which 
would determine their actions. This question can perhaps be 
explored to some extent by electron microscopic localization 
of opioid receptors [ 181. Still another possibility for c(-K dif- 
ferentiation is at the level of receptor-effector relationships 
[4. 50. 781. 
Despite the close correspondence of opioid peptides and 
receptors in many areas, there is no apparent relationship in 
other regions (see also [37,40]). For example, in cerebral 
cortex and hippocampus/dentate gyrus, no immunoreactivity 
could be detected (see also [ 17]), despite clear lamination of 
opioid binding sites in these areas. This discrepancy may be 
due to a relative lack of sensitivity of immunocytochemistry. 
since rhesus monkey cerebral cortex appears to contain 
measurable levels of met-enkephalin-like immunoreactivity 
as determined by radioimmunoassay (unpublished results). 
In rat, also, autoradiographic procedures had demonstrated 
cortical opioid receptors [2] at a time when im- 
munocytochemical studies failed to detect significant corti- 
cal opioid peptide immunoreactivity [II, 69. 76). However. 
as a result of technical improvements, later im- 
munocytochemical studies did show enkephalin and dynor- 
phin perikarya and fibers in rat cerebral cortex [ 12. 13. 27. 
28. 32, 33, 48, 49, 66, 721. 
The purpose of the studies described here was to deter- 
mine whether the anatomical relationship of opioid peptide 
systems and receptors was related to peptide-receptor af- 
finities in vitro. The complexity of the association between 
the multiple opioid systems and apparent p and K opioid 
receptors evidently precludes a straightforward one-to-one 
view of opioid peptide-receptor relationships. Thus. the 
anatomical associations predicted by i/r l*itro receptor 
studies (e.g., enkephalin-6 or dynorphin-rc) are too simplis- 
tic. Indeed, the prediction itself was too simplistic, since it is 
now known that the dynorphin and enkephalin precursors 
can give rise to a diversity of opioids with widely differing 
receptor selectivities. For example, some extended 
proenkephalin peptides have p and K activity [57], while the 
K selectivity of dynorphin A is lost upon COOH-terminal 
cleavage [9,57]. Since differential processing of 
proenkephalin and prodynorphin can give rise 10 opioids of 
varying receptor selectivities. the colocalization of opioid 
receptor subtypes may signify that such processing is a key 
regulatory event in determining which receptor subtype is 
activated and, thus, the physiological consequences of 
opioid neurotransmission. 
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